{"nctId":"NCT00794664","briefTitle":"Safety and Efficacy of Mipomersen in Patients With Severe Hypercholesterolemia on a Maximally Tolerated Lipid-Lowering Regimen and Who Are Not on Apheresis","startDateStruct":{"date":"2009-01"},"conditions":["Hypercholesterolemia","Coronary Heart Disease"],"count":58,"armGroups":[{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]},{"label":"Mipomersen","type":"EXPERIMENTAL","interventionNames":["Drug: Mipomersen"]}],"interventions":[{"name":"Mipomersen","otherNames":["ISIS 301012","Mipomersen sodium","Kynamro™"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Fasting LDL-C ≥200 mg/dL (5.1 mmol/L) at screening and the presence of at least 1 of the following criteria:\n\n  * Myocardial infarction (MI)\n  * Percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG)\n  * Coronary artery disease documented by angiography or any other accepted imaging technique\n  * Positive exercise test (≥1 mm ST-depression at maximal exercise or test terminated because of angina) or a perfusion defect (e.g., thallium or single photon emission computed tomography)\n  * Other clinical atherosclerotic diseases: peripheral artery disease, symptomatic carotid artery disease, abdominal aortic aneurysm\n  * Or, if alternative above were not met, fasting LDL-C ≥300 mg/dL (7.8 mmol/L)\n* On stable, maximally tolerated statin therapy for 8 weeks\n* On stable, medication from an additional class of hypolipidemic agents for 8 weeks.\n* On stable, low fat diet for 12 weeks\n* Stable weight for 6 weeks\n\nExclusion Criteria:\n\n* Significant health problems in the recent past including heart attack, stroke, coronary syndrome, unstable angina, heart failure, significant arrhythmia, hypertension, blood disorders, liver disease, cancer, digestive disorders, Type I diabetes, or uncontrolled Type II diabetes\n* Apheresis within 3 months prior to Screening or expected to start apheresis during the treatment phase","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Primary Efficacy Time Point","description":"LDL-C was measured in mg/dL. Samples were taken following an overnight fast. For patients with triglycerides \\<400 mg/dL, LDL-C was obtained using Friedewald's calculation; and for patients with triglycerides \\>=400 mg/dL, LDL-C was directly measured by the central laboratory using ultracentrifugation. Baseline was defined as the average of the screening and Study Day 1 (pre-treatment) assessments. An assessment was not included in this calculation if it was associated with a non-fasting blood draw or was drawn more than 4 weeks prior to Study Day 1. The PET was the post-baseline visit, for which LDL-C was assessed, closest to 14 days after the last dose of study drug.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.5","spread":"46.87"},{"groupId":"OG001","value":"-35.9","spread":"24.71"}]}]}]},{"type":"PRIMARY","title":"LDL-C at Baseline and the Primary Efficacy Time Point (PET)","description":"The PET was the post-baseline visit, for which LDL-C was assessed, closest to 14 days after the last dose of study drug.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"249.4","spread":"84.3"},{"groupId":"OG001","value":"276.1","spread":"72.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"263.9","spread":"102.0"},{"groupId":"OG001","value":"174.9","spread":"82.8"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Apolipoprotein B (Apo-B) at Primary Efficacy Time Point","description":"Apo-B was measured in mg/dL. Samples were taken following an overnight fast. Baseline was defined as the average of the screening and Study Day 1 (pre-treatment) assessments. An assessment was not included in this calculation if it was associated with a non-fasting blood draw or was drawn more than 4 weeks prior to Study Day 1. The PET was the post-baseline visit, for which LDL-C was assessed, closest to 14 days after the last dose of study drug.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.41","spread":"36.80"},{"groupId":"OG001","value":"-35.88","spread":"22.95"}]}]}]},{"type":"SECONDARY","title":"Apo-B at Baseline and the Primary Efficacy Time Point (PET)","description":"The PET was the post-baseline visit, for which LDL-C was assessed, closest to 14 days after the last dose of study drug.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"182.8","spread":"48.6"},{"groupId":"OG001","value":"202.1","spread":"49.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"193.7","spread":"54.2"},{"groupId":"OG001","value":"126.8","spread":"49.6"}]}]}]},{"type":"SECONDARY","title":"Percentage Change From Baseline in Total Cholesterol at Primary Efficacy Time Point (PET)","description":"Total cholesterol was measured in mg/dL. Samples were taken following an overnight fast. Baseline was defined as the average of the screening and Study Day 1 (pre-treatment) assessments. An assessment was not included in this calculation if it was associated with a non-fasting blood draw or was drawn more than 4 weeks prior to Study Day 1. The PET was the post-baseline visit, for which LDL-C was assessed, closest to 14 days after the last dose of study drug.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.13","spread":"34.74"},{"groupId":"OG001","value":"-28.31","spread":"20.43"}]}]}]},{"type":"SECONDARY","title":"Total Cholesterol at Baseline and the Primary Efficacy Time Point (PET)","description":"The PET was the post-baseline visit, for which LDL-C was assessed, closest to 14 days after the last dose of study drug.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"320.6","spread":"87.2"},{"groupId":"OG001","value":"356.8","spread":"77.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"341.5","spread":"100.5"},{"groupId":"OG001","value":"251.5","spread":"82.2"}]}]}]},{"type":"SECONDARY","title":"Percentage Change From Baseline in Non-High-Density Lipoprotein Cholesterol (Non-HDL-C) at Primary Efficacy Time Point (PET)","description":"Non-HDL-C was measured in mg/dL. Samples were taken following an overnight fast. Baseline was defined as the average of the screening and Study Day 1 (pre-treatment) assessments. An assessment was not included in this calculation if it was associated with a non-fasting blood draw or was drawn more than 4 weeks prior to Study Day 1. The PET was the post-baseline visit, for which LDL-C was assessed, closest to 14 days after the last dose of study drug.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.17","spread":"47.75"},{"groupId":"OG001","value":"-33.95","spread":"23.80"}]}]}]},{"type":"SECONDARY","title":"Non-HDL-C at Baseline and the Primary Efficacy Time Point (PET)","description":"The PET was the post-baseline visit, for which LDL-C was assessed, closest to 14 days after the last dose of study drug.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"277.5","spread":"88.3"},{"groupId":"OG001","value":"305.6","spread":"78.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"296.7","spread":"103.8"},{"groupId":"OG001","value":"198.1","spread":"85.3"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percentage Change From Baseline in Triglycerides at Primary Efficacy Time Point (PET)","description":"Triglycerides were measured in mg/dL. Samples were taken following an overnight fast. Baseline was defined as the average of the screening and Study Day 1 (pre-treatment) assessments. An assessment was not included in this calculation if it was associated with a non-fasting blood draw or was drawn more than 4 weeks prior to Study Day 1. The PET was the post-baseline visit, for which LDL-C was assessed, closest to 14 days after the last dose of study drug.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26.50","spread":"60.61"},{"groupId":"OG001","value":"-8.71","spread":"40.10"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Triglycerides at Baseline and the Primary Efficacy Time Point (PET)","description":"The PET was the post-baseline visit, for which LDL-C was assessed, closest to 14 days after the last dose of study drug.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"140.3","spread":"49.8"},{"groupId":"OG001","value":"142.2","spread":"86.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"164.5","spread":"61.2"},{"groupId":"OG001","value":"116.3","spread":"63.3"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percentage Change From Baseline in Lipoprotein(a) at Primary Efficacy Time Point (PET)","description":"Lipoprotein(a) was measured in mg/dL. Samples were taken following an overnight fast. Baseline was defined as the average of the screening and Study Day 1 (pre-treatment) assessments. An assessment was not included in this calculation if it was associated with a non-fasting blood draw or was drawn more than 4 weeks prior to Study Day 1. The PET was the post-baseline visit, for which LDL-C was assessed, closest to 14 days after the last dose of study drug.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.46","spread":"25.74"},{"groupId":"OG001","value":"-32.65","spread":"32.98"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Lipoprotein(a) at Baseline and the Primary Efficacy Time Point (PET)","description":"The PET was the post-baseline visit, for which LDL-C was assessed, closest to 14 days after the last dose of study drug.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32.4","spread":"28.5"},{"groupId":"OG001","value":"61.3","spread":"68.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"32.1","spread":"28.1"},{"groupId":"OG001","value":"43.3","spread":"54.3"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percentage Change From Baseline in Very-Low-Density Lipoprotein Cholesterol (VLDL-C) at Primary Efficacy Time Point (PET)","description":"VLDL-C was measured in mg/dL. Samples were taken following an overnight fast. Baseline was defined as the average of the screening and Study Day 1 (pre-treatment) assessments. An assessment was not included in this calculation if it was associated with a non-fasting blood draw or was drawn more than 4 weeks prior to Study Day 1. The PET was the post-baseline visit, for which LDL-C was assessed, closest to 14 days after the last dose of study drug.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25.13","spread":"58.66"},{"groupId":"OG001","value":"-9.36","spread":"39.57"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"VLDL-C at Baseline and the Primary Efficacy Time Point (PET)","description":"The PET was the post-baseline visit, for which LDL-C was assessed, closest to 14 days after the last dose of study drug.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28.1","spread":"9.9"},{"groupId":"OG001","value":"29.1","spread":"20.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"32.8","spread":"12.3"},{"groupId":"OG001","value":"23.2","spread":"12.6"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Change From Baseline in Ratio of Low-density Lipoprotein Cholesterol (LDL-C) to High-density Lipoprotein Cholesterol (HDL-C) at Primary Efficacy Time Point (PET)","description":"LDL-C and HDL-C were measured in mg/dL. Samples were taken following an overnight fast. Baseline was defined as the average of the screening and Study Day 1 (pre-treatment) assessments. An assessment was not included in this calculation if it was associated with a non-fasting blood draw or was drawn more than 4 weeks prior to Study Day 1. The PET was the post-baseline visit, for which LDL-C was assessed, closest to 14 days after the last dose of study drug.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.9","spread":null},{"groupId":"OG001","value":"-41.8","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Ratio of LDL-C to HDL-C at Baseline and the Primary Efficacy Time Point (PET)","description":"The PET was the post-baseline visit, for which LDL-C was assessed, closest to 14 days after the last dose of study drug.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.89","spread":null},{"groupId":"OG001","value":"5.21","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.85","spread":null},{"groupId":"OG001","value":"3.05","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percent Change From Baseline in Apolipoprotein A1 (Apo-A1) at Primary Efficacy Time Point (PET)","description":"Apo-A1 was measured in mg/dL. Samples were taken following an overnight fast. Baseline was defined as the average of the screening and Study Day 1 (pre-treatment) assessments. An assessment was not included in this calculation if it was associated with a non-fasting blood draw or was drawn more than 4 weeks prior to Study Day 1. The PET was the post-baseline visit, for which LDL-C was assessed, closest to 14 days after the last dose of study drug.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.75","spread":"14.33"},{"groupId":"OG001","value":"-3.04","spread":"15.76"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Apo-A1 at Baseline and the Primary Efficacy Time Point (PET)","description":"The PET was the post-baseline visit, for which LDL-C was assessed, closest to 14 days after the last dose of study drug.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"139.2","spread":"32.6"},{"groupId":"OG001","value":"154.9","spread":"31.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"140.7","spread":"34.2"},{"groupId":"OG001","value":"147.9","spread":"27.0"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percentage Change From Baseline in High-Density Lipoprotein Cholesterol (HDL-C) at Primary Efficacy Time Point (PET)","description":"HDL-C was measured in mg/dL. Samples were taken following an overnight fast. Baseline was defined as the average of the screening and Study Day 1 (pre-treatment) assessments. An assessment was not included in this calculation if it was associated with a non-fasting blood draw or was drawn more than 4 weeks prior to Study Day 1. The PET was the post-baseline visit, for which LDL-C was assessed, closest to 14 days after the last dose of study drug.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.16","spread":"16.50"},{"groupId":"OG001","value":"5.78","spread":"21.25"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"HDL-C at Baseline and the Primary Efficacy Time Point (PET)","description":"The PET was the post-baseline visit, for which LDL-C was assessed, closest to 14 days after the last dose of study drug.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"43.1","spread":"11.6"},{"groupId":"OG001","value":"51.1","spread":"15.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"44.8","spread":"16.3"},{"groupId":"OG001","value":"53.4","spread":"16.7"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":19},"commonTop":["Injection site erythema","Injection site pain","Injection site pruritus","Injection site haematoma","Injection site swelling"]}}}